BIL 226

Drug Profile

BIL 226

Alternative Names: BIL 226XX

Latest Information Update: 21 Aug 1997

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 21 Aug 1997 A preclinical study has been added to the pharmacodynamics section
  • 14 Dec 1994 Discontinued-Preclinical for Inflammation (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top